Country Reports

Post-COVID and with a national-level strategy in place to bolster its traditional strengths as well as spearhead entry into new sectors, Hong Kong has reason for optimism once again. One of two special administrative regions (SARs) in southern China with separate laws and regulations to the rest of the country, Hong Kong has had to…

Despite its small population size, Hong Kong has long held a strategic interest for the healthcare and life sciences industries, whether as a testbed for innovative products and service delivery models as a result of its efficient regulatory approval system or as an incubator for start-up companies looking to penetrate both mainland Chinese and international…

This report offers companies, investors, policymakers, and stakeholders crucial insight into the rich ecosystem of pharmaceuticals, biotech, and healthcare companies in Hong Kong, based on in-depth interviews conducted with leaders and pioneers across the value chain, from government representatives, country managers of the world’s leading biopharmaceutical companies, representatives from local SMEs and service providers, and…